• Vaccine Ontology ID: VO_0004321
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Rainbow trout
• G glycoprotein gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pCMV4 expressed the infectious hematopoietic necrosis virus (IHNV) glycoprotein (Anderson et al., 1996).
  • Detailed Gene Information: Click Here.
• Vector: pCMV4 (Anderson et al., 1996)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004322
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Rainbow trout
• N gene gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pCMV4 expressed the infectious hematopoietic necrosis virus (IHNV) nucleoprotein (Anderson et al., 1996).
  • Detailed Gene Information: Click Here.
• Vector: pCMV4 (Anderson et al., 1996)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004495
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Fish
• G glycoprotein gene engineering:
  • Type: DNA vaccine construction
  • Description: The pcDNA3.1(+) vector expressed viral glycoproteins (G proteins) (Lorenzen et al., 2002).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3.1(+) vector (Lorenzen et al., 2002)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011398
• Type: DNA vaccine
• Status: Research
• Antigen: Infectious Hematopoietic Necrosis Virus glycoprotein antigen
• G glycoprotein gene engineering:
  • Type: DNA vaccine construction
  • Description: The open reading frame of the G gene of IHNV WRAC strain was amplifed by reverse transcriptase-polymerase chain reaction using sequence-specic primers and cloned into the pT7-blue vector (Novagen, Madison, WI). The gene was then subcloned downstream of the immediate-early enhancer-promoter sequences of human cytomegalovirus (CMV) of the pCDNA 3.1 vector (Invitrogen). The resulting plasmid was designated pIHNw-G (previously pCDNA-G) (Corbeil et al., 2000).
  • Detailed Gene Information: Click Here.
• Vector: pCDNA 3.1 vector (Invitrogen)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0002979
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Rainbow trout
• NV gene engineering:
  • Type: Gene mutation
  • Description: This NV mutant is from Infectious hematopoietic necrosis virus (Thoulouze et al., 2004).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intraperitoneal injection (i.p.)

Rainbow trout Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Fish injected with the glycoprotein-encoding plasmid pCMV4-G, either alone or in combination with the nucleoprotein-encoding plasmid pCMV4-N, generated glycoprotein-specific and virus-neutralizing antibody responses (Anderson et al., 1996).
• Efficacy: The vaccinated fish were protected from subsequent IHNV challenge (Anderson et al., 1996).

Rainbow trout Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: Fish receiving pCMV4-N and pCMV4-G were protected from subsequent IHNV challenge (Anderson et al., 1996).

Rainbow trout Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: Challenge experiments revealed that immunity established shortly after vaccination was cross-protective between IHNV and VHSV whereas no increased survival was found upon challenge with bacterial pathogens. Within two months after vaccination, the cross-protection disappeared while the specific immunity to homologous virus remained high (Lorenzen et al., 2002).

Rainbow trout Response

• Vaccination Protocol: Fish from cohort 1 were used for viral challenge experiments, serological analyses, histology, and passive transfer experiments 1 and 2. For these studies two groups of 500 juvenile rainbow trout from cohort 1 (mean weight 2.5 g) were anaesthetized by immersion in 100 μg/ml tricaine methane sulfonate (MS-222; Argent Chemical Laboratories, Redmond, WA) and vaccinated by i.m. injection with 0.1 μg of either pIHNw-G or pLuc in a total volume of 50 μl phosphate buffered saline (PBS). A group of 200 fish was left unhandled, and all fish were maintained at 12 °C for the entire study period (Kurath et al., 2006).
• Challenge Protocol: . At 25 months post-vaccination a challenge experiment was done with three subgroups of 18 fish per treatment. For each experiment duplicate groups of pIHNw-G vaccinated fish were i.p. injected with IHNV as described above, and the third group was injected with 200 μl MEM without virus. Similarly, two groups of pLuc vaccinated fish were challenged with IHNV, and the third group was mock-challenged (Kurath et al., 2006).
• Efficacy: The DNA vaccine pIHNw-G encodes the glycoprotein of the fish rhabdovirus infectious hematopoietic necrosis virus (IHNV). Vaccine performance in rainbow trout was measured 3, 6, 13, 24, and 25 months after vaccination. At three months all fish vaccinated with 0.1 microg pIHNw-G had detectable neutralizing antibody (NAb) and they were completely protected from lethal IHNV challenge with a relative percent survival (RPS) of 100% compared to control fish (Kurath et al., 2006).

Rainbow trout Response

• Persistence: A NV mutant is attenuated in rainbow trout (Thoulouze et al., 2004).
• Efficacy: An NV mutant induces significant protection in rainbow trout from challenge with wild type IHNV (Thoulouze et al., 2004).